Stock Research for ABIO

ABIO

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ABIO Stock Chart & Research Data

The ABIO chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ABIO chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ABIO Due diligence Resources & Stock Charts

The ABIO stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ABIO Detailed Price Forecast - CNN Money CNN View ABIO Detailed Summary - Google Finance
Yahoo View ABIO Detailed Summary - Yahoo! Finance Zacks View ABIO Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ABIO Trends & Analysis - Trade-Ideas Barrons View ABIO Major Holders - Barrons
NASDAQ View ABIO Call Transcripts - NASDAQ Seeking View ABIO Breaking News & Analysis - Seeking Alpha
Spotlight View ABIO Annual Report - CompanySpotlight.com OTC Report View ABIO OTC Short Report - OTCShortReport.com
TradeKing View ABIO Fundamentals - TradeKing Charts View ABIO SEC Filings - Bar Chart
WSJ View Historical Prices for ABIO - The WSJ Morningstar View Performance/Total Return for ABIO - Morningstar
MarketWatch View the Analyst Estimates for ABIO - MarketWatch CNBC View the Earnings History for ABIO - CNBC
StockMarketWatch View the ABIO Earnings - StockMarketWatch MacroAxis View ABIO Buy or Sell Recommendations - MacroAxis
Bullish View the ABIO Bullish Patterns - American Bulls Short Pains View ABIO Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ABIO Stock Mentions - StockTwits PennyStocks View ABIO Stock Mentions - PennyStockTweets
Twitter View ABIO Stock Mentions - Twitter Invest Hub View ABIO Investment Forum News - Investor Hub
Yahoo View ABIO Stock Mentions - Yahoo! Message Board Seeking Alpha View ABIO Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ABIO - SECform4.com Insider Cow View Insider Transactions for ABIO - Insider Cow
CNBC View ABIO Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ABIO - OTC Markets
Yahoo View Insider Transactions for ABIO - Yahoo! Finance NASDAQ View Institutional Holdings for ABIO - NASDAQ


Stock Charts

FinViz View ABIO Stock Insight & Charts - FinViz.com StockCharts View ABIO Investment Charts - StockCharts.com
BarChart View ABIO Stock Overview & Charts - BarChart Trading View View ABIO User Generated Charts - Trading View




Latest Financial News for ABIO


Zosano Appoints Linda Grais M.D., J.D. to Board of Directors
Posted on Wednesday January 16, 2019

Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced the appointment of Linda Grais, M.D., J.D. to its board of directors. Dr. Grais brings a diverse and important set of experience and expertise to Zosano. After graduation from Yale Medical School and residency at UCSF, she was an assistant professor at UCSF in internal medicine, received her J.D. from Stanford Law School where she was an editor of Stanford Law and Policy Review before joining Wilson Sonsini Goodrich & Rosati as an associate representing Life Science companies.


ARCA biopharma, Inc. (NASDAQ:ABIO) Insiders Have Been Selling
Posted on Wednesday December 26, 2018

We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be remiss not to mention that insider sales have Read More...


ARCA biopharma Updates Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial
Posted on Thursday December 20, 2018

ARCA biopharma, Inc. (ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that it has submitted an amendment to its Special Protocol Assessment (SPA) request to the U.S. Food and Drug Administration (FDA).  The amendment addresses FDA feedback and guidance on the target population for ARCA’s planned Phase 3 clinical trial.  The SPA request is part of the Company’s ongoing interaction with the FDA focused on the planned Phase 3 clinical development program of GencaroTM (bucindolol hydrochloride) as a genetically-targeted treatment for atrial fibrillation (AF) in patients with heart failure (HF). The FDA’s SPA process is designed to facilitate the FDA’s review and approval of drugs by allowing FDA to evaluate the proposed design and size of certain clinical trials that are intended to form the primary basis for determining a drug product’s efficacy and safety.


ARCA biopharma Announces Third Quarter 2018 Financial Results and Provides Corporate Update
Posted on Wednesday November 14, 2018

WESTMINSTER, Colo., Nov. 14, 2018 -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.